COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Pharmacokinetics of Propofol in Morbidly Obese Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01536002
Recruitment Status : Completed
First Posted : February 20, 2012
Last Update Posted : May 31, 2017
Information provided by (Responsible Party):
Tom Heier, Oslo University Hospital

Brief Summary:

The objectives of this study are

  • To determine PK of propofol in bariatric patients
  • To identify the physiological variables that induce propofol PK changes in bariatric patients, when compared to a normal-weight population.
  • To define context-sensitive half-time profiles for propofol in bariatric patients.

Condition or disease Intervention/treatment Phase
Obesity, Morbid Drug: Propofol Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 69 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Pharmacokinetics (PK) of Propofol in Bariatric (Morbidly Obese) Patients
Actual Study Start Date : June 7, 2011
Actual Primary Completion Date : May 7, 2014
Actual Study Completion Date : May 7, 2014

Resource links provided by the National Library of Medicine

Drug Information available for: Propofol

Arm Intervention/treatment
Experimental: Pharmacokinetics
Propofol pharmacokinetics
Drug: Propofol
Intravenous infusion over 30 min of Propofol 3-4 mg/kg body weight
Other Name: Diprivan

Primary Outcome Measures :
  1. Propofol plasma concentrations [ Time Frame: 0-24 hours ]
    Arterial blood samples will be collected 0, 1, 2, 4, 8, 10, 15, 20, 25, 30, 45, 60, 75, 90, 120, 150, 180, 210, 240, 300, 360, 480, 600, 720, and 1440 min after start of propofol bolus infusion. 2 samples will be collected at 0 and 1440 minutes, respectively. The remaining 6 blood samples will be collected according to a block sampling regimen, selected randomly within a time block containing 4 consecutive time points from the time point list noted above. In total 8 samples are drawn from each patient.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Consecutive patients admitted to the Aker University Hospital, scheduled for general or bariatric surgery,
  • Both genders. Female subjects of childbearing potential must be using adequate contraception (i.e. using oral or IM contraception or an IUCD) and must have a negative pregnancy test (urine beta-HCG).
  • Aged 18 - 60 years, both inclusive
  • Body mass index (BMI) ≥ 20 kg/m2
  • Written informed consent

Exclusion Criteria:

  • Patients that are considered not to tolerate a standard dose of propofol administered as a bolus.
  • Known hypersensitivity to propofol or its ingredients (soy, lecithin, glycerol, oil acid)
  • Known hypersensitivity to any of the anesthetic agents to be used
  • Pregnant women
  • Lactating women

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01536002

Layout table for location information
Oslo University Hospital
Oslo, Norway, 0514
Sponsors and Collaborators
Oslo University Hospital
Layout table for investigator information
Principal Investigator: Tom Heier, MD,PhD Oslo University Hospital, Oslo, Norway
Layout table for additonal information
Responsible Party: Tom Heier, Professor, Oslo University Hospital Identifier: NCT01536002    
Other Study ID Numbers: 1.2007.366
First Posted: February 20, 2012    Key Record Dates
Last Update Posted: May 31, 2017
Last Verified: May 2017
Keywords provided by Tom Heier, Oslo University Hospital:
Bariatric surgery
Anesthetics, intravenous
Additional relevant MeSH terms:
Layout table for MeSH terms
Obesity, Morbid
Nutrition Disorders
Body Weight
Hypnotics and Sedatives
Central Nervous System Depressants
Physiological Effects of Drugs
Anesthetics, Intravenous
Anesthetics, General